|Articles|August 12, 2016 (Updated: November 15, 2020)

New CEO for Israel's BioLineRx

August 12, 2016

Tel Aviv, Israel-based BioLineRx Ltd. announced that Philip A. Serlin has been named Chief Executive Officer, effective October 10, 2016. Mr. Serlin joined the company in 2009 as Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who has served as CEO since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

In the current market, the low-hanging fruit of simple predictive modeling has been largely harvested. To maintain a competitive edge, biopharma and biotech firms must now tackle the “untangled complexity” of nature itself. Credit: Stock.Adobe.com/Tierney.

New CEO for Israel's BioLineRx

Newsletter

Related Content

The Multi-Purpose Paradigm: Scaling AI ROI and De-Risking the Life Sciences Value Chain

Delivering Actual Value: Q&A with Sandy Tammisetty

Scaling Medical Digital Transformation in Global Pharma While Ensuring Local Fit

Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care

Conversation Data is a Powerful Tool: How Pharma Organizations Can Use it to Improve Patient Experiences

Trending on PharmExec

Patent Term Extension: Challenges with Defining and Claiming Approved Biologics

Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion

FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria

Real-World Data Brings New Insights to Natural History of Disease Studies

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya